title: The role of menstrual cycle phase and AMH levels in breast cancer patients whose ovarian tissue was cryopreserved for oncofertility treatment.
abstract: OBJECTIVE
  To determine the factors that affect oocyte extraction efficiency when using the "combined procedure". In the present "combined procedure" ovarian tissue cryopreservation and oocyte extraction from an isolated ovary, later used in In Vitro Maturation (IVM), are performed concurrently.
  
  
  METHODS
  Data were analyzed retrospectively and obtained from the clinical records of 27 young breast cancer patients referred for fertility preservation.
  
  
  RESULTS
  The patients' mean age was 33.7 (±3.8) years, mean serum anti-Müllerian hormone (AMH) concentration was 3.5 (±2.1) ng/ml, and mean number of extracted oocytes was 8.3 (±6.1). The phase of menstruation (follicular or luteal) did not affect either the number of oocytes extracted (P = 0.99) nor oocyte survival or maturation rates. Likewise, the number of oocytes that could be extracted was not affected by the type of laparoscopic procedure (multiple-port or single-incision laparoscopy; P = 0.94) or the molecular subtype of breast cancer (either Luminal A or B; P = 0.52). Analysis revealed that the number of extracted oocytes was well-correlated with the patient's AMH serum level and age (coefficient of correlation: 0.60 and -0.48, respectively).
  
  
  CONCLUSIONS
  We conclude that the outcome of the "combined procedure" primarily depends upon the patient's serum AMH level and age. Importantly, the "combined procedure" may be used during any phase of the menstrual cycle to preserve the fertility of breast cancer patients.
authors.affiliation: Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa prefecture, Japan, 216-8511.
authors.forename: Seido
authors.initials: S
authors.lastname: Takae
authors.forename: Yodo
authors.initials: Y
authors.lastname: Sugishita
authors.forename: Nobuhito
authors.initials: N
authors.lastname: Yoshioka
authors.forename: Mariko
authors.initials: M
authors.lastname: Hoshina
authors.forename: Yuki
authors.initials: Y
authors.lastname: Horage
authors.forename: Yorino
authors.initials: Y
authors.lastname: Sato
authors.forename: Chie
authors.initials: C
authors.lastname: Nishijima
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kawamura
authors.forename: Nao
authors.initials: N
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000367:Age Factors; D054304:Anti-Mullerian Hormone / Q000097:blood*; D001943:Breast Neoplasms / Q000378:metabolism / Q000601:surgery; D015925:Cryopreservation; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D059471:In Vitro Oocyte Maturation Techniques; D008597:Menstrual Cycle / Q000502:physiology*; D009865:Oocytes; D010053:Ovary / Q000502:physiology*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D054304:Anti-Mullerian Hormone